The Role of Neurologists and Neuro-ophthalmologists in the Diagnosis and Management of Neuromyelitis Optica Spectrum Disorder

Wednesday, May 27, 2020

7:00 – 8:15 PM ET

7:00 PM Eastern; 6:00 PM Central; 5:00 PM Mountain; 4:00 PM Pacific

Activity Description

This case-based live activity will cover the treatment and management of patients with NMOSD.

Target Audience

This activity is designed to meet the educational needs of US-based neurologists, neuro-ophthalmologists, and emergency physicians who treat patients with NMOSD.

Educational Objectives

Upon the completion of this program, attendees should be able to:

  • Describe dysfunctional immunologic factors, such as IL-6, and pathways of clinical importance for NMOSD therapy
  • Discuss best practices for early diagnosis of NMOSD, including differential diagnosis and AQP4-IgG testing
  • Review the novel mechanisms of action of emerging treatments for NMOSD and clinical trial data on their safety and efficacy profiles

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

Disclosure of Conflicts of Interest

Brian G. Weinshenker, MD, FRCP(C) receives royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr. Volkmann und Kollegen GbR, and holds the patent of NMO-IgG as a diagnostic test for neuromyelitis optica spectrum disorders, served on adjudication committee for clinical trials in neuromyelitis optica spectrum disorders being conducted by MedImmune/VielaBio and Alexion, and consulted for Chugai/Roche/Genentech and Mitsubishi-Tanabe regarding clinical trials for neuromyelitis optica spectrum disorders.

Planners and Managers

The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, Medical Director of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

Med Learning Group designates this live activity for a maximum of 1.25 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with NMOSD. CNE Credits: 1.25 ANCC Contact Hours.

CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.25 contact hour of continuing nursing education of RNs and APNs.

Provider Information

Jointly provided by Med Learning Group and Ultimate Medical Academy/CCM

Financial Support

This activity is supported by an educational grant from Genentech.



Disclosure of Unlabeled Use

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at

Method of Participation and Request for Credit

There are no fees for participating and receiving CME credit for this live activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the live activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

Contact Information for Questions About the Activity

System Requirements

Performedia requires a modern web browser (Microsoft Edge, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software.

Release date: May 27, 2020
Expiration date: May 27, 2020
Estimated time to completion: 1.25 hours